22nd Century Group Inc. (NYSE:XXII) showing dropped/jumped of 0.950% and closed at $2.15, after gaining total volume of 331,828.00 shares. Its earnings per share (EPS) is -$0.15 and its beta value stands at 3.06 points and has total market capitalization of $82.61 million and a total of 90.70 million outstanding shares.
22nd Century Group Inc. (XXII) on February 28, 2017announced that the Company has received written feedback from the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration (FDA) on the Company’s “BRAND A” Modified Risk Tobacco Product (MRTP) application. 22nd Century received feedback from the FDA in conjunction with the Company’s withdrawal of its MRTP application in order to file an even more expansive and robust MRTP application that will include additional scientific data and information from already completed clinical studies on the Company’s Very Low Nicotine (VLN) tobacco cigarettes.
The MRTP application for BRAND A requests that CTP allow 22nd Century to be able to state as truthful and accurate in BRAND A packaging and advertising that the Company’s proprietary VLN cigarettes reduce smokers’ exposure to nicotine because the Company’s proprietary VLN tobacco contains 95% less nicotine than the tobacco contained in conventional tobacco cigarettes. The Company’s keystone technology is its ability to grow proprietary VLN tobacco that contains up to 95% less nicotine than conventional tobacco plants.
In response to the CTP’s clarifying guidance, the Company intends to bifurcate its combined MRTP application into a separate Premarket Tobacco Product (PMT) application and a separate MRTP application for BRAND A to enjoy the benefit of the CTP/FDA’s shorter review period for PMT applications as compared to MRTP applications. In response to the FDA’s request, 22nd Century’s revised MRTP application will also include additional scientific data and information from already completed clinical studies on the Company’s VLN tobacco cigarettes. The Company anticipates filing its more expansive and robust PMT application and MRTP application later this year.
“We are encouraged by CTP/FDA’s feedback on our MRTP application and we look forward to working cooperatively with the FDA to obtain the Agency’s approval to market BRAND A as an over-the-counter, modified risk tobacco product that significantly reduces smokers’ exposure to nicotine,” explained Henry Sicignano, III, President and CEO of 22nd Century Group.
Earth Science Tech Inc (OTCMKTS:ETST) reported the up of 5.24% and closed at $2.04, with the total traded volume of 23,859.00 million shares. During last trade its minimum price was $111,291.00 and it gained its highest price of $2.09 and has a total of 40.91 million outstanding shares.
On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.
Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)
Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.
“I love my work, especially when it allows me to bring my passion for health and business development together, and to bring them to other people,’ says Foster-Cunningham. “This project is my new baby, and I’m excited about the prospects of helping it grow to maturity.”
Based on her experience and success in building and managing teams, developing structures and business models, and driving long term projects; Earth Science Pharmaceutical is confident that she embodies all the assets the company needs to make the project a success.
Innovative Industrial Properties, Inc. (NYSE:IIPR) increased 2.70% closed at $17.50 and traded with total volume of 19,706.00 million shares, while the average trading remained 27,855.00 shares. During last trade its minimum price was $17.01 and it gained the highest price of $17.60. Its market capitalization was $57.08 billion.
Innovative Industrial Properties, Inc. (NYSE:IIPR) on March 14, 2017 announced it will report results for its fourth quarter ended December 31, 2016 and period from June 15, 2016 (date of incorporation) through December 31, 2016 after the market closes on Wednesday, March 22, 2017.
Alan Gold, Executive Chairman, Paul Smithers, President and Chief Executive Officer, and Robert Sistek, Chief Financial Officer and Executive Vice President, Investments, will host an investor conference at 10:00 a.m. Pacific Time on Thursday, March 23, 2017, to discuss the company’s financial results and operations for 2016.
The call will be available through a live audio web cast at the Investor Relations section of the company’s web site at www.innovativeindustrialproperties.com, or live by calling 1-866-807-9684 (domestic) or 1-412-317-5415 (international) and asking to be joined to the Innovative Industrial Properties, Inc. conference call. The complete webcast will be archived for 90 days on the company’s web site. A telephone playback of the conference call will also be available from 12:00 p.m. Pacific Time on Thursday, March 23, 2017 until 12:00 p.m. Pacific Time on Thursday, March 30, 2017 by calling 1-877-344-7529 (domestic), 1-855-669-9658 (Canada) or 1-412-317-0088 (international) and using access code 10103239.